Cleveland biolabs inc (CBLI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-3,162

-3,707

-9,842

-2,590

-13,044

35

-20,129

-22,414

-5,229

-26,671

-12,826

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

13

18

-

-

-

-

-

-

-

-

-

Non-cash investment income

-

31

-

-

-

-

-

-

-

-

-

Depreciation

-

-

21

63

140

200

376

479

512

389

357

Amortization of loan costs

-

-

-

-

135

640

94

-

13

17

-

Gain on debt extinguishment

-

-

-

-

184

0

-

-

-

-

-

Unrealized currency gain on short-term investments

-

-

54

43

17

0

-

-52

-

-

-

Gain on equipment disposal

50

35

6

180

25

-24

3

-18

-

-

-

Investment loss provision

-

-

-

-43

-1,060

0

-

-

-

-

-

Impairment loss on property and equipment

-

-

-

-

-

-

293

-

-

-

-

Non-cash compensation

-

-

-

13

96

496

1,473

2,535

4,044

6,662

-

Warrant issuance costs

-

-

-

-

617

171

-

244

150

-

-

Equity in loss of Incuron, LLC

-

-

-

-

-362

-285

-

-

-

-

-

Change in value of warrant liability

-72

-962

4,426

-3,099

221

-2,662

-2,864

-7,701

-19,821

-

-

Gain on deconsolidation of Incuron, LLC

-

-

-

-

-

14,206

-

-

-

-

-

Patent costs

-

-

-

-

-

-

-

-

1,481

-

-

Changes in operating assets and liabilities:
Warrant issuance costs

-

-

-

-

-

-

-

-

-

-231

-

Change in value of warrant liability

-

-

-

-

-

-

-

-

-

16,011

-

Amortization

-

-

-

-

-

-

-

-

-

-

4

Noncash compensation

-

-

-

-

-

-

-

-

-

-

3,730

Warrant issuance costs

-

-

-

-

-

-

-

-

-

-

266

Change in value of warrant liability

-

-

-

-

-

-

-

-

-

-

-6,267

Patent costs

-

-

-

-

-

-

-

-

-

-

35

Accounts receivable and other current assets

-

-

144

-300

414

-629

416

-1,736

-3,641

1,990

2,347

Other current assets

-

-

-

-174

286

1

-697

182

-

-

-

Accounts receivable and other current assets

68

-431

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-123

611

-139

Other long-term assets

-11

0

0

3

-13

-15

29

6

0

8

-

Accounts payable and accrued expenses

-

-

-1,010

124

-833

459

-713

609

-348

53

106

Accounts payable and accrued expenses

664

-325

-

-

-

-

-

-

-

29

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

264

Net cash used in operating activities

-2,663

-4,613

-

-

-

-

-

-

-16,905

-5,899

-4,244

Deferred revenue

-

-

-

-12

-130

-756

-2,062

3,238

-2,317

-12

-35

Accrued expenses

-

-

-

171

209

213

180

740

845

-

-208

Net cash used in operating activities

-

-

-6,611

-5,039

-12,080

-14,455

-23,102

-20,649

-

-

-

Cash flows from investing activities:
Purchase of short-term investments

1,243

7,737

8,631

17,225

16,873

1,408

-

5,220

-5,520

-

-

Sale of short-term investments

1,351

11,695

12,515

22,712

3,184

1,689

2,197

8,312

434

-

-

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

459

-

Sale of short-term investments

-

-

-

-

-

-

-

-

-

-

1,000

Purchase of equipment

1

27

4

10

19

20

139

178

655

465

136

Proceeds from sale of equipment

50

36

8

198

25

-

-

-

-

-

-

Investment in patents

-

-

-

-

-

-

-

-

326

250

237

Net cash provided by investing activities

156

3,966

-

-

-

-

-

-

-6,066

-1,175

626

Cash flows from financing activities:
Proceeds from sale of Incuron, LLC

-

-

-

-

3,000

0

-

-

-

-

-

Decrease in restricted cash

-

-

-

2

-407

-

-

-

-

-

-

Cash divested upon deconsolidation of Incuron, LLC

-

-

-

-

-

2,048

-

-

-

-

-

Decrease in restricted cash

-

-

-

-

-

0

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

1,497

1,541

-

-

-

Net cash provided by investing activities

-

-

3,887

5,673

-10,276

-1,786

560

1,371

-

-

-

Exercise of warrants

-

55

0

-

-

-

-

-

949

418

414

Net proceeds from issuance of preferred stock

-

-

-

-

-

-

-

-

-

-

4,441

Issuance of common stock, net of offering costs

-

-

-

-

27,190

9,697

-

15,675

21,946

12,234

-

Net repayment of long-term debt

-

-

-

-

-2,664

-4,176

7,327

-

-

-

-

Noncontrolling interest capital contribution to Incuron, LLC

-

-

-

-

-

5,152

-

5,893

-

-

-

Exercise of warrants

-

-

-

539

417

0

-

-

-

-

-

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

936

Exercise of options

-

-

-

-

-

-

12

2

532

901

362

Repayment of capital lease obligation

-

-

-

-

7

83

78

52

-

-

-

Net cash provided by financing activities

-

-

0

539

24,935

10,590

7,261

21,519

-

-

-

Net cash provided by financing activities

-

55

-

-

-

-

-

-

34,769

17,065

4,281

Effect of exchange rate change on cash and equivalents

15

-21

52

-189

235

-1,292

-323

538

156

-34

-

Decrease in cash and cash equivalents

-2,491

-613

-2,671

983

2,814

-6,944

-15,603

2,779

11,954

9,955

663

Supplemental disclosure of cash flow information:
Cash paid during the period for interest

-

-

0

0

517

451

17

23

-

-

-

Cashless exercise of warrants

-

-

4,334

0

-

-

-

-

-

-

-

Debt to equity conversion

-

-

-

-

1,846

0

-

-

-

-

-

Repurchase of treasury stock

-

-

-

-

906

0

-

-

-

-

-

Conversion of warrant liability to equity upon warrant exercise

-

-

-

-

-

-

-

-

995

2,020

874

Cashless exercise of warrants

-

-

-

-

-

-

-

-

207

227

-

Noncash warrant issuance costs

-

-

-

-

-

15

117

-

19

-

-

Equipment acquired through lease financing

-

-

-

-

-

-

-

221

-

-

-

Noncash warrant issuance costs

-

-

-

-

-

-

-

-

-

91

-